Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Excess mortality in acromegaly.

I M Holdaway1

  • 1Department of Endocrinology, Greenlane Clinical Centre, Auckland City Hospital, Auckland, New Zealand. ian@adhb.govt.nz

Hormone Research
|February 7, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Three-year experience with access to nationally funded growth hormone (GH) replacement for GH-deficient adults.

Clinical endocrinology·2014
Same author

Comparison of two low-dose calcium infusion schedules for localization of insulinomas by selective pancreatic arterial injection with hepatic venous sampling for insulin.

Clinical endocrinology·2013
Same author

A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly.

European journal of endocrinology·2008
Same author

Acute retinal pigment epitheliitis associated with intravenous bisphosphonate.

The British journal of ophthalmology·2006
Same author

Serum IGF-I levels are similar in Samoan, Māori and European populations despite differences in body composition.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society·2006
Same author

Oncogenic osteomalacia: culprit tumour detection whole body magnetic resonance imaging.

Internal medicine journal·2003
Same journal

Abstracts of the LWPES/ESPE 8th Joint Meeting Global Care in Paediatric Endocrinology, in collaboration with APEG, APPES, JSPE and SLEP. New York City, New York, USA. September 9-12, 2009.

Hormone research·2011
Same journal

Abstracts of the 47th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Istanbul, Turkey. September 20-23, 2008.

Hormone research·2011
Same journal

Abstracts of the 46th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Helsinki, Finland. June 27-30, 2007.

Hormone research·2011
Same journal

Genetic and pathogenetic aspects of Noonan syndrome and related disorders.

Hormone research·2009
Same journal

Response to growth hormone in short children with Noonan syndrome: correlation to genotype.

Hormone research·2009
Same journal

Growth hormone and the heart in Noonan syndrome.

Hormone research·2009
See all related articles

Acromegaly patients face higher mortality, but improved treatment guidelines and growth hormone (GH) control significantly enhance outcomes. Normal insulin-like growth factor-I (IGF-I) levels are key predictors of success.

Area of Science:

  • Endocrinology
  • Metabolic Disorders

Background:

  • Acromegaly, characterized by excess growth hormone (GH) and insulin-like growth factor-I (IGF-I), is linked to a doubled mortality rate.
  • Standardized mortality ratios in acromegaly patients range from 1.2 to 3.6 compared to the general population.

Purpose of the Study:

  • To evaluate the impact of updated treatment guidelines and novel GH control methods on acromegaly patient outcomes.
  • To identify key predictors of mortality and treatment success in acromegaly.

Main Methods:

  • Multivariate analysis of patient data to determine outcome predictors.
  • Review of recent reports on treatment guidelines and GH/IGF-I control methods.

Main Results:

  • Post-treatment serum GH and IGF-I levels are powerful predictors of patient outcome.

Related Experiment Videos

  • Normal IGF-I concentrations and GH levels <2.5 microg/l (radioimmunoassay) correlate with optimal outcomes.
  • Hypertension and delayed diagnosis adversely affect mortality.

    • Conclusions:

    • Adoption of current treatment guidelines and achieving target GH/IGF-I ranges has improved acromegaly patient outcomes.
    • Newer methods for controlling GH oversecretion contribute to better patient prognosis.